Ventyx Biosciences, Inc. (VTYX)

Market Cap	251.23M
Revenue (ttm)	n/a
Net Income (ttm)	-192.96M
Shares Out	59.25M
EPS (ttm)	-3.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350,883
Open	4.320
Previous Close	4.350
Day's Range	4.220 - 4.450
52-Week Range	1.865 - 40.580
Beta	0.27
Analysts	Buy
Price Target	20.50 (+383.49%)
Earnings Date	May 9, 2024

About VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflamm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 21, 2021
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: VTYX

Analyst Forecast

According to 9 analysts, the average rating for VTYX stock is "Buy." The 12-month stock price forecast is $20.5, which is an increase of 383.49% from the latest price.

Price Target

$20.5

(383.49% upside)

Analyst Consensus: Buy